Business Context and Reporting Period
Company: NeuroSense Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: August 20, 2025
Context: The filing reports on the long-term safety and tolerability of the company's investigational therapy, PrimeC, in patients with Amyotrophic Lateral Sclerosis (ALS).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates rather than financial performance.
Material Changes and Clinical Updates
- Long-Term Exposure: Approximately 20% of participants in the Phase 2a study (including those on compassionate use) have remained on PrimeC for more than 5.5 years.
- Patient History: These patients have lived with ALS for over 7 years.
- Safety Profile: Treatment remains well tolerated across multi-year exposures with no new safety signals observed to date.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future operations, or specific risk factors beyond the implicit context of ongoing clinical development. The primary update is the confirmation of sustained safety in a subset of long-term patients.
Key Facts for Investor Verification
- Verify the total number of patients in the Phase 2a study to contextualize the "approximately 20%" figure.
- Confirm the specific criteria for "compassionate use" patients included in the long-term data.
- Review subsequent filings for any new safety signals or changes in the tolerability profile.
- Check the company's cash runway and funding status in separate financial reports, as this filing contains no liquidity data.